ENT & Neurology & Internal Medicine & Family Medicine
Endolymphatic hydrops (Ménière's disease)
Endolymphatic hydrops - clinically referred to as Ménière's disease - is a disorder of the inner ear characterized by abnormal distension of the endolymphatic compartment of the membranous labyrinth, leading to recurrent attacks of spontaneous rotary vertigo, tinnitus, fluctuating sensorineural deafness and a sensation of auricular fullness. First described in 1861 by Prosper Ménière, who identified the inner ear as the site of this symptomatology previously attributed to the brain, Ménière's disease affects around 200 to 500 people per 100,000 in the general Western population, with an estimated annual prevalence of 0.2 % in Canada. It mainly affects adults between the ages of 40 and 60, with a slight female predominance (F/H ratio 1.3-1.5:1). The pathophysiology is based on an imbalance between the production and resorption of endolymph in the membranous labyrinth - a fluid rich in potassium, poor in sodium and calcium - with progressive accumulation leading to rupture of Reissner's membrane or the membranes of the saccule and utricle, releasing endolymph into the perilymph and precipitating the clinical crisis. Diagnosis is based on the Barany Society consensus criteria (2015, revised 2020) - which distinguish between definite and probable Meniere's disease - incorporating symptomatic tetralogy, audiometry and exclusion of differential diagnoses. Treatment aims to reduce the frequency and severity of attacks (background therapy), relieve acute attacks (symptomatic therapy) and, in refractory forms, employ unilateral ablative therapies (intratympanic gentamicin injection, surgical labyrinthectomy).
Pathophysiology, diagnostic criteria, and audiological evaluation
- Anatomy of the Inner Ear and Pathophysiology of Endolymphatic Hydrops: anatomy of the membranous labyrinth and fluid compartments: bony labyrinth → hollows into the rock of the temporal bone + contains the membranous labyrinth + separated by two fluid spaces: perilymph (between the bony and membranous labyrinth): composition close to CSF → rich in Na⁺ (148 mEq/L) + poor in K⁺ (5 mEq/L) → produced by the spiral ligament and vascular stria + endolymph (inside the membranous labyrinth): inverse plasma composition → rich in K⁺ (150 mEq/L) + poor in Na⁺ (1 mEq/L) + electronegative medium → produced by the vascular striatum (endolymphatic sac and canal) → reabsorbed by the endolymphatic sac (distal part of the membranous labyrinth in the cerebellopontine angle) → role in electrochemical transduction: endocochlear potential (+80 mV) → generated by vascular striatum → potential difference that actuates hair cells → K⁺ exits hair cells (depolarization) → electrical flow → cochlear + vestibular nerve action potential; pathophysiology of endolymphatic hydrops: imbalance between endolymph production and resorption → accumulation of endolymph → progressive distension of membranous labyrinth → hydrops → 3 potential mechanisms discussed: abnormality of resorption in the endolymphatic sac (main hypothesis - mechanical obstruction + fibrosis + sac atrophy) + overproduction of endolymph by the vascular striatum + abnormality of ionic regulation (Na⁺/K⁺-ATPase ion channels + aquaporins - AQP1 + AQP2 + AQP6) → Horner 1993 - Laryngoscope: reduction of endolymphatic sac area and function in anatomical specimens from Ménière patients + Friis 2002 - Acta Otolaryngologica: importance of aquaporins in regulating endolymphatic volume + progressive distension → saccule + utricle + cochlear duct → rupture of membranes (Reissner's membrane) → endolymph-perilymph mixture → massive ionic disturbance → K⁺ intoxication of vestibular and cochlear nerve cells → clinical crisis of vertigo + tinnitus + deafness → then spontaneous repair of membrane → resolution of crisis → with each crisis: cumulative damage to hair cells → long-term progressive deafness; etiological and triggering factors: idiopathic in the majority of cases (primary Meniere's disease) → associated factors discussed: autoimmune dysregulation: anti-endolymphatic sac antibodies + anti-inner ear proteins + atopic terrain (Harris 1983 - Archives of Otolaryngology) + viral infections (herpes simplex HSV-1 latent in spiral ganglion - Arnold 1996 - ENT) → HSV-1 as trigger of inflammation + vascular factor (migraines + vasospasm of the arteries of the rock - Nuti 2019 - Journal of Vestibular Research) → frequent Meniere-migraine association (vestibular migraine differential) + hereditary factor: familial forms in 5-15 % of cases + mutations in COCH + MYH9 + SLC26A4 + KCNJ10 genes described in syndromic forms → Lyme bacteria: Borrelia burgdorferi → has been proposed as a trigger → insufficient data to establish a causal relationship + attack-triggering factors: psychological stress + fatigue + high sodium intake + alcohol + caffeine + barometric fluctuations + menstruation (in some patients)
- Diagnostic Criteria and Assessment — Barany Society Classification 2015/2020: Criteria for definite Ménière's disease (Definite Ménière's Disease — Lempert 2015 — Journal of Vestibular Research + Bisdorff 2020 — Journal of Vestibular Research): A — At least 2 spontaneous episodes of rotatory vertigo lasting between 20 minutes and 12 hours → duration ≥20 min: distinguishes it from vestibular neuritis (lasting >24h) and BPPV (lasting <1 min) + b — surdité neurosensorielle basse fréquence ou toutes fréquences (audiométrie) dans l'oreille atteinte avant pendant après au moins un épisode vertigineux → audiométrie : perte ≥30 db hl à 2 des 3 suivantes 250 500 1 000 hz (aao-hns 1995) de basses documentée c acouphènes fluctuants sensation plénitude auriculaire d non attribuable une autre cause exclusion diagnostics différentiels ; maladie ménière probable (probable ménière's disease) a épisodes vertige-prévertige d'une durée 20 minutes 24 heures l'audiométrie n'est pas requise mais recommandée évaluation audiologique détaillée tonale (pta pure tone audiometry) audiogramme caractère fluctuant la entre les crises initialement sur (courbe en u ascendante) évolue vers pantonale progressive stade précoce ≥15–20 avancé ≥50 aao-hns staging 1995 pta moyen ≤25 26–40 41–70 4>70 dB → vocal: speech discrimination often preserved initially + ECoG (electrocochleography): recording of cochlear evoked potentials → SP/AP ratio (Summating Potential / Action Potential) → SP/AP ≥0.4: suggestive of endolymphatic hydrops → sensitivity 60-75 % + specificity 75-90 % → adjunctive test (not mandatory but provides additional diagnostic value) → VHIT (Video Head Impulse Test): assesses vestibulo-ocular reflex (VOR) → often normal in Meniere's disease between attacks (unlike vestibular neuritis) + ENG / VNG (electronystagmography / videonystagmography): caloric test → ipsilateral canal hyporeflexia (canal paralysis) progressive as disease progresses → VEMPS (Vestibular Evoked Myogenic Potentials): cVEMP (cervical) → evaluates saccule → often impaired in Meniere's disease + oVEMP (ocular) → evaluates utricle → High-resolution labyrinthine MRI with intravenous or intratympanic gadolinium (Gd-DTPA): direct visualization of endolymphatic hydrops → reference method for anatomical confirmation of hydrops → Nakashima 2010 - Annals of the New York Academy of Sciences: MRI after intratympanic gadolinium injection → hydrops visible as an endolymphatic signal defect → sensitivity 80-90 % + in the process of standardization + not available everywhere + PET-CT or CT of the rock: exclude a tumor of the cerebellopontine angle (vestibular schwannoma - acoustic neuroma)
Treatment and care
| Intervention | Data, methods and results | Key studies and recommendations |
|---|---|---|
| Management of acute vertigo episodes Antihistamines — benzodiazepines — antiemetics — rest — duration — rehydration — vestibulolytics |
Goals of acute attack treatment: reduce intensity of vertigo + control nausea-vomiting + allow patient to rest → attack lasts spontaneously 20 minutes to 12 hours → most attacks do not require hospital management; vestibulolytic (vestibular suppression) drugs: vestibulolytics reduce central vestibular signal → relief of vertigo + nausea → use during attack only (not as background treatment - they inhibit central vestibular compensation): meclizine (Antivert - Bonamine): anticholinergic H1 antihistamine → 25-50 mg PO + dose can be repeated every 4-6h → available over the counter in Canada → main outpatient crisis treatment → dimenhydrinate (Gravol): antihistamine-anticholinergic → 50 mg PO or IM or IR → available over the counter → alternative to meclizine + prochlorperazine (Stemetil): antidopaminergic + potent antiemetic → 10 mg PO or IM → for intense vomiting → risk of tardive dyskinesia if prolonged use → benzodiazepines (diazepam + lorazepam): GABA-A agonists → reduction of vestibular nucleus activity → diazepam 5-10 mg IV or PO → lorazepam 0.5-1 mg sublingual (rapid onset of action) → very effective on vertigo + anxiety associated with crisis → reserve for severe crises + short duration + risk of dependence if prolonged use → metopimazine (Vogalen): phenothiazine antiemetic → 15 mg sublingual during crisis → available in France + over-the-counter in Quebec in some pharmacies → effective for nausea-vomiting → ondansetron (Zofran): setron antiemetic → 4-8 mg IV or sublingual → less sedative → useful if severe vomiting + betahistine: discussed lower (mainly background treatment) → rest in the dark + comfortable lying position + eyes closed → reduction of conflicting visual afferents → oral hydration if tolerable → ginger (Zingiber officinale): modest reduction of nausea during vertigo → supplements without adverse effects → office management: if the attack is severe + significant vomiting + inability to get up → medical consultation or emergency → IM antiemetics (prochlorperazine + dimenhydrinate) + IV hydration → work-up if first attack (exclude a central cause - cerebellar stroke) → 1st episode of rotatory vertigo → brain imaging work-up (brain MRI) if doubt about etiology | Crisis treatment data: Hain 2021 - Hearing Research: review of vestibulolytics in Meniere's crises → meclizine + dimenhydrinate → well-established efficacy + manageable sedative effects + Strupp 2011 - New England Journal of Medicine (review): vertigo and its treatment - vestibulolytics recommended for crisis + benzodiazepines → effective but risk of dependence → limit to very disabling crises → Murdin 2016 - Cochrane Review: drugs for vertigo → limited high-quality evidence for most agents + but clinically validated use → AAO-HNS 2020 Ménière Guidelines (Basura - Otolaryngology Head and Neck Surgery): vestibulolytics recommended for crisis → betahistine recommended as background treatment + European Academy of Neurology (Strupp 2022 - EAN Guidelines): crisis treatment → meclizine or diazepam or lorazepam + antiemetics → betahistine for background + SRC (Royal Canadian Society) + AAN: no Meniere-specific guideline but follow AAO-HNS |
| Background treatment — reducing seizure frequency Betahistine — diuretics — low-sodium diet — elimination of triggers — immunosuppressants — results — quality of life |
Low-sodium diet and lifestyle modification: sodium restriction: <1,500-2,000 mg Na/d (3.8-5.1 g salt/d) → non-pharmacological basis of background treatment → rational: reduce systemic osmotic pressure → reduce endolymph production → avoid sodium-rich foods (cold cuts + potato chips + cheese + industrial broths + ready meals) + reduce caffeine + alcohol (cochlear vasodilators + vestibular destabilizers) + stress management → relaxation + yoga + CBT → stress is a documented trigger of attacks + regular sleep + moderate physical activity + stop smoking → Sajjadi 2008 - Otolaryngologic Clinics : hygienic-dietary measures → seizure reduction in 50-60 % of patients + strong placebo effect in this disease (30-40 % seizure reduction on placebo) → Tassinari 2015 - Journal of Vestibular Research: impact of low-salt diet on seizures + cohort study; betahistine (Serc - 8 mg or 16 mg or 24 mg): most prescribed background drug treatment in Europe and Canada → mechanism: H1 agonist + H3 antagonist → vasodilation of the cochlear microcirculation + modulation of the vestibular histaminergic system → reduction in endolymphatic pressure → meta-analysis Strupp 2017 - Journal of Neurology: betahistine → reduction in the frequency of vertigo attacks by 40-50 % vs placebo in several observational studies + RCT BEMED Trial (Adrion 2016 - British Medical Journal): double-blind multicenter randomized trial n=221 → betahistine 48 mg/d vs 144 mg/d vs placebo × 9 months → no significant difference in seizure reduction between the 3 groups → disappointing result + much debated in the ENT community + interpretation: patient selection (BEMED included patients without mandatory audiogram) + insufficient duration (9 months) + imprecise seizure measurement tool + James 2011 - Cochrane Review: betahistine → insufficient data for a strong recommendation → nevertheless: used worldwide + well tolerated + few adverse effects + some experts maintain its use at high doses (48-144 mg/d) + guidelines position: AAO-HNS 2020: betahistine mentioned but conditional recommendation in the absence of high-quality evidence + awaiting new data → widespread use in clinical practice in Quebec and Europe; diuretics: hydrochlorothiazide + triamterene (Dyazide) + furosemide + acetazolamide → mechanism: reduction of endolymph volume by natriuresis + renal action → Thirlwall 2006 - Cochrane Review: diuretics in Meniere's disease → limited data → tendency to reduce attacks → frequent clinical use despite limited evidence → monitor kalemia (hypokalemia under HCTZ alone) + renal function → prefer combination HCTZ + triamterene (potassium sparing) → betahistine + diuretic: combination frequently used in practice → not validated in combined RCT; immunosuppressants: systemic corticoids (prednisone 1 mg/kg/d × 1-2 weeks): indicated if autoimmune etiology suspected + during exacerbation phases → intratympanic injection of methylprednisolone (ITM - transtympanic steroid injection): Silverstein 1998 - Otolaryngology HNS + Garduno-Anaya 2005 - Otolaryngology HNS: intratympanic injection of methylprednisolone or dexamethasone → variable but safe results → reduction of attacks in 40-70 % of patients → alternative between conventional medical treatment and intratympanic gentamicin → ITM dexamethasone 4-8 mg/mL → series of injections (3-5 in 2 weeks) → advantage: preserves hearing function + potential anti-hydrops effect → used as 2nd line before resorting to gentamicin; magnesium: 535 mg/d → modest effect on attacks in some studies + good tolerance + melatonin: improves sleep + indirect reduction in stress/sleep-triggered attacks → acupuncture + alternative medicine: insufficient data but common practice → significant placebo in Meniere's disease | Fundamental data on background treatment: Adrion 2016 - British Medical Journal (BEMED RCT n=221): betahistine 48 mg/d + 144 mg/d + placebo → no significant difference → result controversial in the community → but criticized for its inclusion criteria and measurement tools + Strupp 2017 - Journal of Neurology: review on betahistine → several positive studies → meta-analysis overall in favor → high-dose betahistine (144 mg/d) more effective → BEMED insufficiently powerful to conclude on this dose + James 2011 - Cochrane Review: betahistine → insufficient data to formally conclude → consensual use nonetheless + Thirlwall 2006 - Cochrane Review: diuretics → positive trend inconclusive → Tassinari 2015 - JVR: low-salt diet + cohort + seizure reduction + Garduno-Anaya 2005 - Otolaryngology HNS: ITM methylprednisolone → seizure reduction 40-70 % + AAO-HNS 2020 (Basura - Otolaryngology Head and Neck Surgery): practical guideline for Meniere's disease → background treatment: conditional betahistine + diuretics + sodium diet + ITM → North American reference + EAN 2022 (Strupp): European recommendations + Tassinari 2015 JVR: low-salt diet demonstrated impact |
| Treatments for refractory Meniere's disease — intratympanic gentamicin injections and surgery Intratympanic gentamicin — chemical labyrinthectomy — endolymphatic sac decompression — vestibular neurectomy — surgical labyrinthectomy — criteria — results — hearing risk |
Intratympanic gentamicin injection (ITG) - unilateral chemical ablative treatment: mechanism: gentamicin (aminoglycoside) → selective ototoxicity on vestibular hair cells (type I - coupule cells) → unilateral partial or total vestibular denervation → reduction of homolateral vestibular signaling → elimination or reduction of vertigo attacks by chemical ablation of diseased labyrinth → Nedzelski 1993 - Laryngoscope: intratympanic gentamicin → protocol + results → vertigo control in 80-90 % of cases → most effective method among non-surgical treatments → protocols: single dose (single low-dose protocol): gentamicin 12-40 mg/mL + transtyp. injection. single → repeat after 4 weeks if dizziness persists → advantage: less auditory risk + multidose protocol: 3-4 injections in 1-3 weeks → higher control rate + greater risk of deafness → prefer low-dose protocol with wait for effect (4-6 weeks) → Silverstein 2009 - Otolaryngology HNS + Postema 2008 - Acta Otolaryngologica: meta-analysis → dizziness control: 75-95 % depending on protocol → risk of increased deafness: 10-30 % depending on dose → auditory risk is the main drawback → reserve for ears with hearing already significantly impaired + or if patient accepts risk → shared decision-making + vestibular deafferentation induces progressive central compensation (reprogramming by cerebellum) → vestibular re-education recommended after ITG → improved balance + quality of life; endolymphatic sac decompression (DSE - Endolymphatic Sac Surgery): principle: mastoidectomy + opening of the mastoid → decompression and drainage of the endolymphatic sac in the dura mater of the posterior fossa → objective: improve endolymph resorption → controversial: a major meta-analysis Thomsen 1981 - Archives of Otolaryngology (placebo-surgery trial): DSE vs sham surgery → no significant difference → controversy persists but surgery still performed → Silverstein 2003 - Laryngoscope + Kaylie 2005 - Otolaryngology HNS: case series → seizure reduction in 60-75 % of cases → advantage: retains hearing + vestibular neurectomy (surgical section of vestibular nerve): principle: section of vestibular nerve while preserving cochlear nerve → retrosigmoid or middle fossa route → vertigo control: 90-95 % → hearing preservation: 60-85 % → demanding surgical technique → reserved for very refractory cases with functional hearing to be preserved + experienced neurosurgical surgeon + Gianoli 1998 - Otolaryngology HNS: vestibular neurectomy → excellent vertigo control + surgical labyrinthectomy: complete removal of membranous labyrinth (cochlear + vestibular structures) → results in total deafness in operated ear → reserved if hearing already totally lost on affected side + uncontrollable vertigo → vertigo control : 95-100 % → cochlear hearing aid (cochlear implant) if bilateralization + bilateral Meniere's (10-15 % of patients): more delicate therapeutic approach → avoid bilateral destructive treatments → prefer IT corticoids + high-dose betahistine + vestibular rehabilitation + cochlear implant if severe bilateral deafness | Fundamental data on ablative treatments: Nedzelski 1993 - Laryngoscope: gentamicin IT → single-dose protocol → control 80-90 % → reference standard + Postema 2008 - Acta Otolaryngologica (meta-analysis): gentamicin IT → vertigo control 75-95 % → auditory risk 10-30 % depending on dose → better efficacy of multidose protocols but greater auditory risk + Silverstein 2009 - Otolaryngology HNS: low-dose protocol repeated → good efficacy/risk ratio + Thomsen 1981 - Archives of Otolaryngology: randomized trial DSE vs placebo → no difference → controversial but DSE remains practiced + Gianoli 1998 - Otolaryngology HNS: vestibular neurectomy → control 90-95 % + Kaylie 2005 - Otolaryngology HNS: revision of DSE + series + AAO-HNS 2020 (Basura - Otolaryngology HNS): practical guidelines → gentamicin IT recommended for refractory single-ear Ménière + after failure of conservative treatments → EAN 2022: gentamicin IT + vestibular neurectomy → validated options for refractory Ménière |
| Differential diagnosis, long-term outcome, and vestibular rehabilitation Differential diagnosis — BPPV — vestibular neuritis — vestibular migraine — schwannoma — progression — bilaterality — rehabilitation — quality of life |
Differential diagnosis with Meniere's disease - pathologies to exclude: benign paroxysmal positional vertigo (BPPV): very short duration (24h often several days) + no deafness + pathological VHIT → treatment: systemic corticosteroids + vestibular rehabilitation + vestibular migraine (vestibular migraine): most difficult differential diagnosis with Meniere → recurrent vertigo + associated migraines + photophobia/phonophobia + aura + not necessarily deafness + less frequent tinnitus → ICHD-3 + Barany Society criteria (Lempert 2022) → many probable Meniere's could actually be vestibular migraines → vestibular schwannoma (acoustic neuroma): unilateral progressive deafness + constant unilateral tinnitus + imbalance → pathological VHIT → brain MRI with gadolinium mandatory → mass in internal auditory canal or cerebellopontine angle → idiopathic sudden deafness: single episode of acute deafness + urgent corticosteroid treatment (≤2 weeks after onset) + defer diagnosis of Meniere's → periummphatic fistula: rupture of oval or round window → vertigo + deafness + often after effort or trauma → normal VHIT → surgical exploration if suspected + bilateral otolithic labyrinth (bilateral vestibulopathy): ataxia + oscillopsia + without clear rotatory vertigo → bilateral abnormal VEMPs + perilymphatic : if hypothyroidism → mimic Meniere's → TSH systematically → Cogan syndrome: inflammatory ocular involvement + audio-vestibular involvement → anti-HSP70 antibodies → context of systemic disease; natural course and long-term prognosis: fluctuating disease with phases of activity and remission → in the early years: frequent attacks then often spontaneous attenuation → Meurman 1987 - Archives of Otolaryngology : long-term follow-up → 80 % of patients have spontaneous reduction of attacks after 10-15 years → but: inexorable progressive deafness even in absence of attacks → mean final hearing loss: 50-80 dB in 20 years + bilateralization: 10-15 % of Meniere's develop bilateral involvement → often years after initial involvement → systematic monitoring of contralateral ear → impaired quality of life: anxiety anticipating attacks + social isolation + professional limitations + depression → psychological care + support groups + CBT + psycho-education about the disease + professional implications: absolute contraindication to professional driving (bus + truck + cab driver) + work at height + risky activities → medical declaration according to provincial rules; vestibular rehabilitation (VRT - Vestibular Rehabilitation Therapy): after chemical or surgical labyrinthectomy + or inter-crisis to improve central compensation → gaze stabilization exercises (VOR adaptation) + habituation → improved balance + walking + quality of life → Hillier 2019 - Cochrane Review: VRT → demonstrated efficacy in improving balance and quality of life in vestibular dysfunction → recommended after ITG or vestibular neurectomy | Data on differential diagnosis and evolution: Meurman 1987 - Archives of Otolaryngology: long-term follow-up → spontaneous reduction of attacks in 80 % after 10-15 years + but progressive deafness → Lempert 2015 + 2022 - Journal of Vestibular Research: criteria Barany Society Ménière + vestibular migraine → essential clinical distinction + Hillier 2019 - Cochrane Review: VRT → efficacy for balance and quality of life + Strupp 2022 - EAN Guidelines: Meniere treatment + differential diagnosis → summary of European recommendations → Nakashima 2010 - ANYAS: gadolinium MRI + visible endolymphatic hydrops → clinical correlation + AAO-HNS 2020 Basura - Otolaryngology Head and Neck Surgery: North American reference practice guidelines → diagnosis + background treatment + refractory treatment + follow-up + Basura 2020 - Otolaryngology HNS: AAO-HNS 1995 revised classification + comprehensive guideline + Lempert 2022 - JVR: Barany Society 2022 updated criteria for Meniere's disease and vestibular migraine |
ℹ️
Meniere's disease requires a rigorous clinical diagnosis — the first episode of intense rotational vertigo warrants a brain MRI to rule out a schwannoma or a cerebellar stroke. The 2015/2020 Barany Society criteria require at least 2 episodes of vertigo lasting from 20 minutes to 12 hours, documented sensorineural hearing loss in the affected ear, and exclusion of differential diagnoses. Vestibular migraine is the most common and most difficult differential diagnosis to distinguish in clinical practice. Biannual audiometry is essential for monitoring hearing loss progression.
Situations Requiring Urgent Consultation
First episode of intense rotary vertigo + nausea + vomiting, especially if associated with central neurological symptoms (severe headache + diplopia + dysarthria + gait ataxia + swallowing difficulties) → rule out cerebellar or brainstem stroke → call 911 or immediate emergency services → emergency brain MRI → never assume the first episode of vertigo is Meniere's disease or BPPV without imaging if central signs are present.
Sudden unilateral hearing loss (loss ≥30 dB over 3 consecutive frequencies in less than 72 hours) with or without associated vertigo → Sudden idiopathic hearing loss → ENT emergency → Systemic corticosteroids to be initiated within 2 weeks (ideally within 24–48 hours) → Intratympanic corticosteroid injection as a second-line treatment → Urgent audiometric evaluation + MRI if schwannoma is suspected → Do not delay treatment.
Atypical, very prolonged Meniere's disease (>12-24 hours) resistant to usual treatment + associated cerebellar signs → consult emergency room → brain MRI + vestibular assessment → rule out vestibular neuritis + stroke → IV treatment (dimenhydrinate + hydration) if significant vomiting.
Meniere's disease followed by a sudden fall without prodrome (drop attack or Tumarkin's otolithic crisis) → Tumarkin's otolithic crises: sudden falls without loss of consciousness linked to otolithic discharge → risk of injury → urgent ENT consultation → discuss intratympanic gentamicin injection for vestibular ablation → contraindication to driving + risky activities until treatment.
Consult at Clinique Omicron
Clinique Omicron physicians assess recurrent vertigo and symptomatology suggestive of endolymphatic hydrops, prescribe audiometric and appropriate imaging assessments, initiate foundational medical treatment (betahistine + diuretics + lifestyle modifications), and acute crisis treatment (vestibulolytics), and refer patients to ENT or the neurology-ENT team for specialized procedures. Consultations are available at multiple service points across Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not replace the advice of a doctor or a specialist in ENT or vestibular neurology. Any first episode of intense dizziness, especially in a patient with no known history, warrants a medical evaluation to rule out a serious cause.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.